Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pediatric Vouchers Can Have Heavy Adult Involvement, FDA Says

Executive Summary

Draft guidance says sponsors remain eligible for rare pediatric disease priority review voucher even if they enroll also adults in clinical trials.

You may also be interested in...



What Is A Rare Pediatric Disease? US FDA's Orphan Products Office Hopes To Update Guidance On Definition

The Office of Pediatric Therapeutics is working with the Office of Orphan Products Development to make rare pediatric disease determinations, which can help sponsors obtain a priority review voucher.

Priority Review Weirdness: Tropical Voucher Sells For More; Owner Says It’s Worth Less

Knight Therapeutics says a rare pediatric disease voucher is more valuable than its tropical disease voucher despite the sale price.

Ebola Drugs Take Center Stage In Review Voucher Bill, But Real Value May Be Harmonization

Along with adding Ebola to list of disease treatments eligible for tropical disease priority review voucher, bill moving through Congress would cut notification time required before redemption.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS056496

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel